Literature DB >> 26857458

Adjuvant chemotherapy versus concurrent chemoradiotherapy for high-risk cervical cancer after radical hysterectomy and systematic lymphadenectomy.

Munetaka Takekuma1, Yuka Kasamatsu2, Nobuhiro Kado2, Shiho Kuji2, Aki Tanaka2, Nobutaka Takahashi2, Masakazu Abe2, Yasuyuki Hirashima2.   

Abstract

BACKGROUND: The aims of this study were to evaluate the efficacy and toxicity of chemotherapy (CT) compared with concurrent chemoradiotherapy (CCRT) after radical hysterectomy and lymphadenectomy in high-risk patients with early-stage cervical cancer and to evaluate whether the radicality of the lymphadenectomy would affect the outcome and toxicity of postoperative adjuvant therapy.
METHODS: The cases of all patients (n = 393) with FIGO IB1-IIB cervical cancer who were treated by radical surgery at Shizuoka Cancer Center between January 2002 and December 2013 were reviewed. Of these, 111 patients met the inclusion criteria for this retrospective study: (1) high risk for occurrence due to pathologically confirmed parametrial invasion and/or pelvic lymph node metastasis; (2) postoperative treatment with adjuvant CT or CCRT. The clinical data of these patients were reviewed.
RESULTS: Of the 111 patients, 37 and 74 patients underwent CT and CCRT, respectively. The 4-year progression-free survival rate [PFS; 71.7 (CT) vs. 68.3 % (CCRT)] and overall survival rate [76.0 (CT) vs. 82.7 % (CCRT)] did not differ significantly between the two groups. The CT group contained significantly more patients with severe neutropenia than the CCRT group (66.7 vs. 23.0 %, respectively; p < 0.001), and the CCRT group contained significantly more patients with diarrhea than the CT group (10.8 vs. 0 %, respectively; p = 0.04). The patients who had ≥40 lymph nodes dissected (≥40 group) had higher PFS than the patients who had <40 lymph nodes dissected (<40 group) (73.2 vs. 64.2 %, respectively), although the difference was not significant. In the CT group, there was no significant association between the number of dissected lymph nodes and severe toxicities. However, in the CCRT group, significantly more vomiting (p = 0.046) and edema (p = 0.046) occurred in the ≥40 group than in the <40 group.
CONCLUSIONS: Chemotherapy after surgery for high-risk patients had similar efficacy and a different toxicity profile compared with CCRT, and a more radical surgical procedure would improve the survival outcome. However, CCRT was associated with worse toxicity than CT. We advocate a prospective randomized study to compare CT with CCRT for patients with high-risk factors for recurrence.

Entities:  

Keywords:  CCRT; Cervical cancer; Chemotherapy; Postoperative adjuvant therapy

Mesh:

Year:  2016        PMID: 26857458     DOI: 10.1007/s10147-016-0955-3

Source DB:  PubMed          Journal:  Int J Clin Oncol        ISSN: 1341-9625            Impact factor:   3.402


  15 in total

1.  Carcinoma of the cervix uteri.

Authors:  J L Benedet; F Odicino; P Maisonneuve; U Beller; W T Creasman; A P Heintz; H Y Ngan; M Sideri; S Pecorelli
Journal:  J Epidemiol Biostat       Date:  2001

2.  Treatment of cervical cancer with adjuvant chemotherapy versus adjuvant radiotherapy after radical hysterectomy and systematic lymphadenectomy.

Authors:  Masayoshi Hosaka; Hidemichi Watari; Mahito Takeda; Masashi Moriwaki; Yoko Hara; Yukiharu Todo; Yasuhiko Ebina; Noriaki Sakuragi
Journal:  J Obstet Gynaecol Res       Date:  2008-08       Impact factor: 1.730

3.  Reconsideration of postoperative concurrent chemoradiotherapy with fluorouracil and cisplatin for uterine cervical cancer.

Authors:  Munetaka Takekuma; Yuka Kasamatsu; Nobuhiro Kado; Shiho Kuji; Aki Tanaka; Nobutaka Takahashi; Masakazu Abe; Yasuyuki Hirashima
Journal:  J Obstet Gynaecol Res       Date:  2015-07-14       Impact factor: 1.730

4.  Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer.

Authors:  M Morris; P J Eifel; J Lu; P W Grigsby; C Levenback; R E Stevens; M Rotman; D M Gershenson; D G Mutch
Journal:  N Engl J Med       Date:  1999-04-15       Impact factor: 91.245

5.  Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study.

Authors:  C W Whitney; W Sause; B N Bundy; J H Malfetano; E V Hannigan; W C Fowler; D L Clarke-Pearson; S Y Liao
Journal:  J Clin Oncol       Date:  1999-05       Impact factor: 44.544

6.  Chemotherapy versus radiotherapy versus observation for high-risk cervical carcinoma after radical hysterectomy: A randomized, prospective, multicenter trial.

Authors:  M Lahousen; J Haas; H Pickel; A Hackl; C Kurz; H Ogris; W Stummvoll; R Winter
Journal:  Gynecol Oncol       Date:  1999-05       Impact factor: 5.482

7.  Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix.

Authors:  W A Peters; P Y Liu; R J Barrett; R J Stock; B J Monk; J S Berek; L Souhami; P Grigsby; W Gordon; D S Alberts
Journal:  J Clin Oncol       Date:  2000-04       Impact factor: 44.544

8.  Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma.

Authors:  H M Keys; B N Bundy; F B Stehman; L I Muderspach; W E Chafe; C L Suggs; J L Walker; D Gersell
Journal:  N Engl J Med       Date:  1999-04-15       Impact factor: 91.245

9.  Postoperative adjuvant chemotherapy for node-positive cervical adenocarcinoma.

Authors:  Nobuhiro Takeshima; Kuniko Utsugi; Katsuhiko Hasumi; Ken Takizawa
Journal:  Int J Gynecol Cancer       Date:  2009-02       Impact factor: 3.437

10.  Adjuvant chemotherapy after radical hysterectomy for cervical carcinoma: a comparison with effects of adjuvant radiotherapy.

Authors:  T Iwasaka; T Kamura; M Yokoyama; N Matsuo; H Nakano; H Sugimori
Journal:  Obstet Gynecol       Date:  1998-06       Impact factor: 7.661

View more
  15 in total

1.  Long-term outcomes of postoperative taxane/platinum chemotherapy for early stage cervical cancer: a retrospective study.

Authors:  Mika Okazawa-Sakai; Takanori Yokoyama; Etsuko Fujimoto; Shinichi Okame; Yuko Shiroyama; Takashi Yokoyama; Kazuhiro Takehara
Journal:  Int J Clin Oncol       Date:  2018-02-14       Impact factor: 3.402

Review 2.  Debulking hysterectomy followed by chemoradiotherapy versus chemoradiotherapy for FIGO stage (2019) IB3/II cervical cancer.

Authors:  Manas Chakrabarti; Andy Nordin; Juneida Khodabocus
Journal:  Cochrane Database Syst Rev       Date:  2022-09-16

3.  Systemic therapy for cervical carcinoma - current status.

Authors:  Krystyna Serkies; Jacek Jassem
Journal:  Chin J Cancer Res       Date:  2018-04       Impact factor: 5.087

4.  Prognostic evaluation of postoperative adjuvant therapy for operable cervical cancer: 10 years' experience of National Cancer Center in China.

Authors:  Tong Shu; Dan Zhao; Bin Li; Yating Wang; Shuanghuan Liu; Pingping Li; Jing Zuo; Ping Bai; Rong Zhang; Lingying Wu
Journal:  Chin J Cancer Res       Date:  2017-12       Impact factor: 5.087

5.  Risk factors and a prediction model for lower limb lymphedema following lymphadenectomy in gynecologic cancer: a hospital-based retrospective cohort study.

Authors:  Kenji Kuroda; Yasuhiro Yamamoto; Manami Yanagisawa; Akira Kawata; Naoya Akiba; Kensuke Suzuki; Kazutoshi Naritaka
Journal:  BMC Womens Health       Date:  2017-07-25       Impact factor: 2.809

6.  Phase II study of adjuvant chemotherapy with paclitaxel and nedaplatin for uterine cervical cancer with lymph node metastasis.

Authors:  Munetaka Takekuma; Mototsugu Shimokawa; Shin Nishio; Hideo Omi; Tsutomu Tabata; Yuji Takei; Kaei Nasu; Yoshiyuki Takahashi; Shinji Toyota; Yoshikazu Ichikawa; Atsushi Arakawa; Fuminori Ito; Hiroshi Tsubamoto; Taisuke Mori; Yasuyuki Hirashima; Kimihiko Ito
Journal:  Cancer Sci       Date:  2018-04-15       Impact factor: 6.716

7.  Comparison of Postoperative Adjuvant Chemotherapy and Concurrent Chemoradiotherapy for FIGO2018 Stage IIIC1 Cervical Cancer: A Retrospective Study.

Authors:  Masahiro Kagabu; Takayuki Nagasawa; Shunsuke Tatsuki; Yasuko Fukagawa; Hidetoshi Tomabechi; Eriko Takatori; Yoshitaka Kaido; Tadahiro Shoji; Tsukasa Baba
Journal:  Medicina (Kaunas)       Date:  2021-05-29       Impact factor: 2.430

8.  Comparison between adjuvant chemotherapy and adjuvant radiotherapy/chemoradiotherapy after radical surgery in patients with cervical cancer: a meta-analysis.

Authors:  Kwang Beom Lee; Seung Hyuk Shim; Jong Min Lee
Journal:  J Gynecol Oncol       Date:  2018-04-16       Impact factor: 4.401

9.  Should the Number of Metastatic Pelvic Lymph Nodes be Integrated into the 2018 Figo Staging Classification of Early Stage Cervical Cancer?

Authors:  Luigi Pedone Anchora; Vittoria Carbone; Valerio Gallotta; Francesco Fanfani; Francesco Cosentino; Luigi Carlo Turco; Camilla Fedele; Nicolò Bizzarri; Giovanni Scambia; Gabriella Ferrandina
Journal:  Cancers (Basel)       Date:  2020-06-12       Impact factor: 6.639

10.  Comparison of adenocarcinoma and adenosquamous carcinoma prognoses in Chinese patients with FIGO stage IB-IIA cervical cancer following radical surgery.

Authors:  Xiaojing Zhang; Zunfu Lv; Xiaoxian Xu; Zhuomin Yin; Hanmei Lou
Journal:  BMC Cancer       Date:  2020-07-16       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.